Recurrent Nasopharynx Carcinoma
7
2
3
2
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
28.6%
2 terminated out of 7 trials
50.0%
-36.5% vs benchmark
14%
1 trials in Phase 3/4
200%
4 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer
Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma
BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer